Clinical Research Directory

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Have histologically or cytologically-confirmed adenocarcinoma of the prostate without small cell histology * Have prostate cancer progression while on androgen deprivation therapy (ADT) or post-bilateral orchiectomy * Have received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) (eg, abiraterone acetate, enzalutamide, apalutamide, or darolutamide) for non-metastatic hormone-sensitive prostate cancer (nmHSPC)/androgen pathway modulation sensitive (APMS), metastatic hormone-sensitive prostate cancer (mHSPC)/APMS, non-metastatic castration-resistant prostate cancer (nmCRPC)/ androgen pathway modulation refractory (APMR), or metastatic castration-resistant prostate cancer (mCRPC)/APMR and progressed during or after at least 8 weeks of treatment (≥14 weeks of treatment for participants with bone progression) * Have had prior treatment with poly adenosine diphosphate ribose polymerase inhibitor (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator * Participants with microsatellite instability (MSI)-high/deficient mismatch repair (dMMR) must have received programmed cell death 1 protein (PD-1) blocking antibody-based immunotherapy when indicated by local approved regimen, or be considered ineligible for PD-1-blocking antibody-based immunotherapy by the investigator Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Is unable to swallow tablets/capsules * Has a history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has received prior treatment with taxane-based chemotherapy agent for mCRPC/APMR * Has received prior therapy with trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) or topoisomerase I inhibitor (TOP1i) payload ADC * Has had a "superscan" bone scan * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids, has current pneumonitis/interstitial lung disease, or has suspected interstitial lung disease (ILD) or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening